Skip to main content
Erschienen in: Digestive Diseases and Sciences 4/2011

01.04.2011 | Original Article

Rectal Administration of Lactobacillus casei DG Modifies Flora Composition and Toll-Like Receptor Expression in Colonic Mucosa of Patients with Mild Ulcerative Colitis

verfasst von: Renata D’Incà, Michela Barollo, Marco Scarpa, Alessia Rosaria Grillo, Paola Brun, Maria Grazia Vettorato, Ignazio Castagliuolo, Giacomo Carlo Sturniolo

Erschienen in: Digestive Diseases and Sciences | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

An imbalance in gut microbiota seems to contribute to the development of chronic inflammatory disorders of the gastrointestinal tract, such as ulcerative colitis (UC). Although it has been suggested that probiotic supplementation is an effective approach to colitis, its effects on intestinal flora and on mucosal cytokine balance have never been explored.

Aim

To evaluate the effect of Lactobacillus casei (L. casei) DG, a probiotic strain, on colonic-associated microbiota, mucosal cytokine balance, and toll-like receptor (TLR) expression.

Methods

Twenty-six patients with mild left-sided UC were randomly allocated to one of three groups for an 8-week treatment period: the first group of 7 patients received oral 5-aminosalicylic acid (5-ASA) alone, the second group of 8 patients received oral 5-ASA plus oral L. casei DG, and the third group of 11 patients received oral 5-ASA and rectal L. casei DG. Biopsies were collected from the sigmoid region to culture mucosal-associated microbes and to assess cytokine and TLR messenger RNA (mRNA) levels by quantitative real-time polymerase chain reaction (RT-PCR).

Results

5-ASA alone or together with oral L. casei DG failed to affect colonic flora and TLR expression in a significant manner, but when coupled with rectally administered L. casei DG, it modified colonic microbiota by increasing Lactobacillus spp. and reducing Enterobacteriaceae. It also significantly reduced TLR-4 and interleukin (IL)-1β mRNA levels and significantly increased mucosal IL-10.

Conclusions

Manipulation of mucosal microbiota by L. casei DG and its effects on the mucosal immune system seem to be required to mediate the beneficial activities of probiotics in UC patients.
Literatur
1.
Zurück zum Zitat Kelly D, Conway S, Aminov R. Commensal gut bacteria: Mechanisms of immune modulation. Trends Immunol. 2005;26:326–333.PubMedCrossRef Kelly D, Conway S, Aminov R. Commensal gut bacteria: Mechanisms of immune modulation. Trends Immunol. 2005;26:326–333.PubMedCrossRef
2.
Zurück zum Zitat Sartor RB. Enteric microflora in IBD: Pathogens or commensal? Inflamm. Bowel Dis. 1997;3:230–235.CrossRef Sartor RB. Enteric microflora in IBD: Pathogens or commensal? Inflamm. Bowel Dis. 1997;3:230–235.CrossRef
3.
Zurück zum Zitat Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VLS#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108–114.PubMedCrossRef Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VLS#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108–114.PubMedCrossRef
4.
Zurück zum Zitat Gionchetti P, Rizzello F, Heiwug U, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202–1209.PubMedCrossRef Gionchetti P, Rizzello F, Heiwug U, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202–1209.PubMedCrossRef
5.
Zurück zum Zitat Dotan I, Rachmilewitz D. Probiotics in inflammatory bowel disease: Possible mechanisms of action. Curr Opin Gastroenterol. 2005;21:426–430.PubMed Dotan I, Rachmilewitz D. Probiotics in inflammatory bowel disease: Possible mechanisms of action. Curr Opin Gastroenterol. 2005;21:426–430.PubMed
6.
Zurück zum Zitat White NR, Mulligan P, King PJ, et al. Sodium butyrate-mediated Sp3 acetylation represses human insulin-like growth factor binding protein-3 expression in intestinal epithelial cells. J Pediatric Gastroenterol Nutr. 2006;42:134–141.CrossRef White NR, Mulligan P, King PJ, et al. Sodium butyrate-mediated Sp3 acetylation represses human insulin-like growth factor binding protein-3 expression in intestinal epithelial cells. J Pediatric Gastroenterol Nutr. 2006;42:134–141.CrossRef
7.
Zurück zum Zitat Ewaschuk JB, Walker JW, Diaz H, et al. Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. J Nutr. 2006;136:1483–1487.PubMed Ewaschuk JB, Walker JW, Diaz H, et al. Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. J Nutr. 2006;136:1483–1487.PubMed
8.
Zurück zum Zitat Bassaganya-Riera J, Reynolds K, Martino-Catt S, et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology. 2004;127:777–791.PubMedCrossRef Bassaganya-Riera J, Reynolds K, Martino-Catt S, et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology. 2004;127:777–791.PubMedCrossRef
9.
Zurück zum Zitat Voltan S, Martines D, Elli M, et al. Lactobacillus crispatus M247-Derived H2O2 Acts as a Signal Transducing Molecule Activating Peroxisome Proliferator Activated Receptor-γ in the Intestinal Mucosa. Gastroenterology. 2008;135:1216–1227.PubMedCrossRef Voltan S, Martines D, Elli M, et al. Lactobacillus crispatus M247-Derived H2O2 Acts as a Signal Transducing Molecule Activating Peroxisome Proliferator Activated Receptor-γ in the Intestinal Mucosa. Gastroenterology. 2008;135:1216–1227.PubMedCrossRef
10.
Zurück zum Zitat Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut. 2005;54:1182–1193.PubMedCrossRef Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut. 2005;54:1182–1193.PubMedCrossRef
11.
Zurück zum Zitat Agrawal S, Agrawal A, Doughty B, et al. Cutting edge: Different Toll-like receptors agonist instruct dendritic cells to induce distinct Th responses via different modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol. 2003;171:4984–4989.PubMed Agrawal S, Agrawal A, Doughty B, et al. Cutting edge: Different Toll-like receptors agonist instruct dendritic cells to induce distinct Th responses via different modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol. 2003;171:4984–4989.PubMed
12.
Zurück zum Zitat Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 2004;430:257–263.PubMedCrossRef Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 2004;430:257–263.PubMedCrossRef
13.
Zurück zum Zitat Netea MG, Van der Meer JWM, Kullberg BJ. Toll-like receptors as an escape mechanism from the host defense. Trends Microbiol. 2004;12:484–488.PubMedCrossRef Netea MG, Van der Meer JWM, Kullberg BJ. Toll-like receptors as an escape mechanism from the host defense. Trends Microbiol. 2004;12:484–488.PubMedCrossRef
14.
Zurück zum Zitat Voltan S, Castagliuolo I, Elli M, et al. Aggregating phenotype in Lactobacillus crispatus determines intestinal colonization and TLR2 and TLR4 modulation in murine colonic mucosa. Clin Vaccine Immunol. 2007;14:1138–1148.PubMedCrossRef Voltan S, Castagliuolo I, Elli M, et al. Aggregating phenotype in Lactobacillus crispatus determines intestinal colonization and TLR2 and TLR4 modulation in murine colonic mucosa. Clin Vaccine Immunol. 2007;14:1138–1148.PubMedCrossRef
15.
Zurück zum Zitat Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology. 2007;132:1359–1374.PubMedCrossRef Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology. 2007;132:1359–1374.PubMedCrossRef
16.
Zurück zum Zitat Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000;68:7010–7017.PubMedCrossRef Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000;68:7010–7017.PubMedCrossRef
17.
Zurück zum Zitat Cario E, Podolsky DK. Intestinal epithelial TOLLerance versus inTOLLerance of commensals. Mol Immunol. 2005;42:887–893.PubMedCrossRef Cario E, Podolsky DK. Intestinal epithelial TOLLerance versus inTOLLerance of commensals. Mol Immunol. 2005;42:887–893.PubMedCrossRef
18.
Zurück zum Zitat Castagliuolo I, Galeazzi F, Ferrari S, et al. Beneficial effect of auto-aggregating Lactobacillus crispatus on experimentally induced colitis in mice. FEMS Immunol Med Microbiol. 2005;43:197–204.PubMedCrossRef Castagliuolo I, Galeazzi F, Ferrari S, et al. Beneficial effect of auto-aggregating Lactobacillus crispatus on experimentally induced colitis in mice. FEMS Immunol Med Microbiol. 2005;43:197–204.PubMedCrossRef
19.
Zurück zum Zitat Nanda Kumar NS, Balamurugan R, Jayakanthan K, et al. Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. J Gastroenterol Hepatol. 2008;23:1834–1839.PubMedCrossRef Nanda Kumar NS, Balamurugan R, Jayakanthan K, et al. Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. J Gastroenterol Hepatol. 2008;23:1834–1839.PubMedCrossRef
20.
Zurück zum Zitat Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1963;4:299–315.PubMedCrossRef Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1963;4:299–315.PubMedCrossRef
21.
Zurück zum Zitat Baron J, Connell A, Lennard-Jones A. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964;1:189–192. Baron J, Connell A, Lennard-Jones A. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964;1:189–192.
22.
Zurück zum Zitat Florén CH, Benoni C, Willén R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol. 1987;22:459–462.PubMedCrossRef Florén CH, Benoni C, Willén R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol. 1987;22:459–462.PubMedCrossRef
23.
Zurück zum Zitat Conte MP, Schippa S, Zamboni I, et al. Gut-associated bacterial microbiota in pediatric patients with inflammatory bowel disease. Gut. 2006;55:1760–1767.PubMedCrossRef Conte MP, Schippa S, Zamboni I, et al. Gut-associated bacterial microbiota in pediatric patients with inflammatory bowel disease. Gut. 2006;55:1760–1767.PubMedCrossRef
24.
Zurück zum Zitat Rivas R, Zurdo-Piñeiro EV, Mateos PF, et al. Identification of microorganisms by PCR amplification and sequencing of a universal amplified ribosomal region present in both prokaryotes and eukaryotes. J Microbiol Meth. 2004;56:413–426.CrossRef Rivas R, Zurdo-Piñeiro EV, Mateos PF, et al. Identification of microorganisms by PCR amplification and sequencing of a universal amplified ribosomal region present in both prokaryotes and eukaryotes. J Microbiol Meth. 2004;56:413–426.CrossRef
25.
Zurück zum Zitat Mylonaki M, Rayment NB, Rampton DS, et al. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel diseases. Inflamm Bowel Dis. 2005;11:481–487.PubMedCrossRef Mylonaki M, Rayment NB, Rampton DS, et al. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel diseases. Inflamm Bowel Dis. 2005;11:481–487.PubMedCrossRef
26.
Zurück zum Zitat Seksik P, Rigottier-Gois L, Gramet G. Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon. Gut. 2003;52:237–242.PubMedCrossRef Seksik P, Rigottier-Gois L, Gramet G. Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon. Gut. 2003;52:237–242.PubMedCrossRef
27.
Zurück zum Zitat Penders J, Stobberingh EE, van den Brandt PA, et al. The role of the intestinal microbiota in the development of atopic disorders. Allergy. 2007;62:1223–1236.PubMedCrossRef Penders J, Stobberingh EE, van den Brandt PA, et al. The role of the intestinal microbiota in the development of atopic disorders. Allergy. 2007;62:1223–1236.PubMedCrossRef
28.
Zurück zum Zitat Penders J, Thijs C, van den Brandt PA, et al. Gut microbiota composition and development of atopic manifestations in infancy: The KOALA Birth Cohort Study. Gut. 2007;56:661–667.PubMedCrossRef Penders J, Thijs C, van den Brandt PA, et al. Gut microbiota composition and development of atopic manifestations in infancy: The KOALA Birth Cohort Study. Gut. 2007;56:661–667.PubMedCrossRef
29.
Zurück zum Zitat Ley RE, Bäckhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102:11070–11075.PubMedCrossRef Ley RE, Bäckhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102:11070–11075.PubMedCrossRef
30.
Zurück zum Zitat Shiba T, Aiba Y, Ishikawa H, et al. The suppressive effect of bifidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inflammatory bowel disease. Microbiol Immunol. 2003;47:371–378.PubMed Shiba T, Aiba Y, Ishikawa H, et al. The suppressive effect of bifidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inflammatory bowel disease. Microbiol Immunol. 2003;47:371–378.PubMed
31.
Zurück zum Zitat Sheil B, Shanahan F, O’Mahony L. Probiotic effects on inflammatory bowel disease. J Nutr. 2007;137:819S–824S.PubMed Sheil B, Shanahan F, O’Mahony L. Probiotic effects on inflammatory bowel disease. J Nutr. 2007;137:819S–824S.PubMed
32.
Zurück zum Zitat Gionchetti P, Rizzello F, Heiwug U, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202–1209.PubMedCrossRef Gionchetti P, Rizzello F, Heiwug U, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202–1209.PubMedCrossRef
33.
Zurück zum Zitat Kruis W, Fri P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617–1623.PubMedCrossRef Kruis W, Fri P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617–1623.PubMedCrossRef
34.
Zurück zum Zitat Cui H-H, Chen C-L, Wang J-D, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol. 2004;10:1521–1525.PubMed Cui H-H, Chen C-L, Wang J-D, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol. 2004;10:1521–1525.PubMed
35.
Zurück zum Zitat Suau A, Bonnet R, Sutren M, Gordon JJ, Gibson GR, et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol. 1999;65:4799–4807.PubMed Suau A, Bonnet R, Sutren M, Gordon JJ, Gibson GR, et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol. 1999;65:4799–4807.PubMed
36.
Zurück zum Zitat Bartosch S, Fite A, Macfarlane GT, McMurdo MF. Characteization of bacterial communities in feces from healthy volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the faecal microbiota. Appl Environ Microbiol. 2004;70:3575–3581.PubMedCrossRef Bartosch S, Fite A, Macfarlane GT, McMurdo MF. Characteization of bacterial communities in feces from healthy volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the faecal microbiota. Appl Environ Microbiol. 2004;70:3575–3581.PubMedCrossRef
37.
Zurück zum Zitat Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut micobiota, as revealed by deep 16S rRNA sequencing. PLOS Biol. 2008,6:e280 2383–2400. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut micobiota, as revealed by deep 16S rRNA sequencing. PLOS Biol. 2008,6:e280 2383–2400.
38.
Zurück zum Zitat Morelli L, Garbagna N, Rizzello F, Zonenschain D, Grossi E. In vivo association to human colon of Lactobacillus paracasei B21060: Map from biopsies. Dig Liv Dis. 2006;38:894–898.CrossRef Morelli L, Garbagna N, Rizzello F, Zonenschain D, Grossi E. In vivo association to human colon of Lactobacillus paracasei B21060: Map from biopsies. Dig Liv Dis. 2006;38:894–898.CrossRef
39.
Zurück zum Zitat Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology. 2004;127:412–421.PubMedCrossRef Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology. 2004;127:412–421.PubMedCrossRef
40.
Zurück zum Zitat Swidsinski A, Loening-Baucke V, Herber A. Mucosal flora in Crohn’s disease and ulcerative colitis - an overview. J Physiol Pharmacol. 2009;60(Suppl 6):61–71.PubMed Swidsinski A, Loening-Baucke V, Herber A. Mucosal flora in Crohn’s disease and ulcerative colitis - an overview. J Physiol Pharmacol. 2009;60(Suppl 6):61–71.PubMed
41.
Zurück zum Zitat Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease: Current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl. 2001;234:29–40.PubMedCrossRef Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease: Current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl. 2001;234:29–40.PubMedCrossRef
42.
Zurück zum Zitat Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103–1108.PubMedCrossRef Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103–1108.PubMedCrossRef
43.
Zurück zum Zitat Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol. 2004;5:104–112.PubMedCrossRef Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol. 2004;5:104–112.PubMedCrossRef
44.
Zurück zum Zitat van Baarlen P, Troost FJ, van Hemert S, et al. Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc Natl Acad Sci U S A. 2009;106:2371–2376.PubMedCrossRef van Baarlen P, Troost FJ, van Hemert S, et al. Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc Natl Acad Sci U S A. 2009;106:2371–2376.PubMedCrossRef
45.
46.
Zurück zum Zitat Ortega-Cava CF, Ishihara S, Rumi MAK, et al. Strategic compartmentalization of toll-like receptor 4 in the mouse gut. J Immunol. 2003;170:3977–3985.PubMed Ortega-Cava CF, Ishihara S, Rumi MAK, et al. Strategic compartmentalization of toll-like receptor 4 in the mouse gut. J Immunol. 2003;170:3977–3985.PubMed
47.
Zurück zum Zitat Zhang R, Li Y, Beck PL, et al. Toll-like receptor 4 regulates colitis-associated adenocarcinoma development in interleukin-10-deficient (IL-10(-/-)) mice. Biochem Soc Trans. 2007;35:1375–1376.PubMedCrossRef Zhang R, Li Y, Beck PL, et al. Toll-like receptor 4 regulates colitis-associated adenocarcinoma development in interleukin-10-deficient (IL-10(-/-)) mice. Biochem Soc Trans. 2007;35:1375–1376.PubMedCrossRef
48.
Zurück zum Zitat Masayuki F, Fukata M, Chen A, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007;133:1869–1881.CrossRef Masayuki F, Fukata M, Chen A, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007;133:1869–1881.CrossRef
49.
Zurück zum Zitat Cario E, Gerken G, Podolsky D. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology. 2004;127:224–238.PubMedCrossRef Cario E, Gerken G, Podolsky D. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology. 2004;127:224–238.PubMedCrossRef
50.
Zurück zum Zitat Seo M, Okada M, Yao T, Okabe N, Maeda K, Oh K. Evaluation of disease activity in patients with moderately active ulcerative colitis: Comparisons between a new activity index and Truelove and Witts’ classification. Am J Gastroenterol. 1995;90:1759–1763.PubMed Seo M, Okada M, Yao T, Okabe N, Maeda K, Oh K. Evaluation of disease activity in patients with moderately active ulcerative colitis: Comparisons between a new activity index and Truelove and Witts’ classification. Am J Gastroenterol. 1995;90:1759–1763.PubMed
Metadaten
Titel
Rectal Administration of Lactobacillus casei DG Modifies Flora Composition and Toll-Like Receptor Expression in Colonic Mucosa of Patients with Mild Ulcerative Colitis
verfasst von
Renata D’Incà
Michela Barollo
Marco Scarpa
Alessia Rosaria Grillo
Paola Brun
Maria Grazia Vettorato
Ignazio Castagliuolo
Giacomo Carlo Sturniolo
Publikationsdatum
01.04.2011
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 4/2011
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1384-1

Weitere Artikel der Ausgabe 4/2011

Digestive Diseases and Sciences 4/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.